Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €13.00 EUR
Change Today +0.13 / 1.01%
Volume 11.9K
BCART On Other Exchanges
EN Brussels
As of 11:35 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

biocartis nv (BCART) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/25/15 - €14.95
52 Week Low
04/24/15 - €11.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOCARTIS NV (BCART)

Related News

No related news articles were found.

biocartis nv (BCART) Related Businessweek News

No Related Businessweek News Found

biocartis nv (BCART) Details

Biocartis Group NV engages in the development and marketing of assays in oncology and infectious diseases segments through its molecular diagnostics platform. It is developing assays for oncology, including Idylla BRAF Mutation Test, an In vitro diagnosis assay for the automated detection of B-raf V600 mutations (E/E2/D/K/R/M) in formalin fixed, paraffin embedded samples; KRAS assay, a sample-to-result test that detects 21 mutations in all clinically relevant KRAS codons in colorectal cancers in one cartridge The company’s assays for oncology also comprises Neuroblastoma RAS viral (v-ras) oncogene (NRAS), NRAS/BRAF, and NRAS/BRAF/EGFR492 assays are three sample-to-result tests for the detection of mutations in the extended series of 19 NRAS mutations and Serine/threonine-protein kinase B-raf (BRAF) codon 600 for the NRAS/BRAF assay, as well as the epidermal growth factor receptor S492R mutation for the NRAS/ BRAF/EGFR492 assays, as well as MSI assay for colorectal cancers and liquid biopsy testing assays. In addition, it developing Idylla-Enrich, a pre-enrichment platform for bloodstream infections, intended to be used in conjunction with the sepsis assay; Influenza Virus—Respiratory Syncytial Virus, a respiratory tract panel assay; and a respiratory MP (mixed panel) assay; human immunodeficiency, and hepatitis C virus viral load assays; and an Ebola assay. The company has a license and development agreement with Janssen Pharmaceutica NV and bioMérieux SA; and a framework collaboration agreement with Abbott Molecular. Biocartis Group NV was founded in 2007 and is based in Mechelen, Belgium.

189 Employees
Last Reported Date: 04/14/15
Founded in 2007

biocartis nv (BCART) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biocartis nv (BCART) Key Developments

Biocartis Group NV Auditor Raises 'Going Concern' Doubt

Biocartis Group NV filed its Annual on Apr 14, 2015 for the period ending Dec 31, 2014. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Biocartis SA Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 03:00 PM

Biocartis SA Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 03:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Rudi Pauwels, Chief Executive Officer, Executive Chairman, and Founder.

Biocartis and VIB Announce Exclusive License Agreement on a Novel Panel of Microsatellite Instability

Biocartis and VIB announced their exclusive license agreement on a novel panel of microsatellite instability (MSI) biomarkers for several cancers, in particular colorectal cancer (CRC). This agreement will enable Biocartis to develop a unique and user-friendly assay, whereby MSI biomarkers can simply and rapidly be detected by Biocartis' molecular diagnostics platform Idylla(TM). Microsatellite instability (MSI) is one of the premier molecular markers in CRC but is also important in ovarian, endometrial and gastric cancers. MSI evolves as a result of inactivation of the DNA mismatch repair (MMR) system and can be found in approximately 15% of all CRCs. As a result of the license agreement with VIB, Biocartis will develop a new CRC assay for MSI biomarker detection. MSI-testing is vastly underused due to the technical complexity of the current laboratory-developed assays. The availability of a simple and user-friendly assay on Biocartis' Idylla(TM) platform has the potential to unlock greatly this considerable market.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCART:BB €13.00 EUR +0.13

BCART Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCART.
View Industry Companies

Industry Analysis


Industry Average

Valuation BCART Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCARTIS NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at